With focus on inflammation and pain

Key strength No.1

Unique and protected technology platform

Key strength No.1

Unique mode of action

Unique mode of action –
5-HT2 receptor antagonism.

Unique platform

Unique platform with four different chemical classes.

Unique stability

Unique stability – financial and organisational.

Phase II

AMAP102 has successfully completed Phase I. The Phase II trial is planned to start second half 2012.

News News
AnaMars lead clinical development project (incl. AMAP102) was granted
a US patent April 3, 2012.